Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I - PubMed (original) (raw)

Multicenter Study

. 2010 Feb 15;207(2):291-7.

doi: 10.1084/jem.20091983. Epub 2010 Feb 1.

Rainer Döffinger, Angels Natividad, Maya Chrabieh, Gabriela Barcenas-Morales, Capucine Picard, Aurélie Cobat, Marie Ouachée-Chardin, Antoine Toulon, Jacinta Bustamante, Saleh Al-Muhsen, Mohammed Al-Owain, Peter D Arkwright, Colm Costigan, Vivienne McConnell, Andrew J Cant, Mario Abinun, Michel Polak, Pierre-François Bougnères, Dinakantha Kumararatne, László Marodi, Amit Nahum, Chaim Roifman, Stéphane Blanche, Alain Fischer, Christine Bodemer, Laurent Abel, Desa Lilic, Jean-Laurent Casanova

Affiliations

Multicenter Study

Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I

Anne Puel et al. J Exp Med. 2010.

Abstract

Most patients with autoimmune polyendocrine syndrome type I (APS-I) display chronic mucocutaneous candidiasis (CMC). We hypothesized that this CMC might result from autoimmunity to interleukin (IL)-17 cytokines. We found high titers of autoantibodies (auto-Abs) against IL-17A, IL-17F, and/or IL-22 in the sera of all 33 patients tested, as detected by multiplex particle-based flow cytometry. The auto-Abs against IL-17A, IL-17F, and IL-22 were specific in the five patients tested, as shown by Western blotting. The auto-Abs against IL-17A were neutralizing in the only patient tested, as shown by bioassays of IL-17A activity. None of the 37 healthy controls and none of the 103 patients with other autoimmune disorders tested had such auto-Abs. None of the patients with APS-I had auto-Abs against cytokines previously shown to cause other well-defined clinical syndromes in other patients (IL-6, interferon [IFN]-gamma, or granulocyte/macrophage colony-stimulating factor) or against other cytokines (IL-1beta, IL-10, IL-12, IL-18, IL-21, IL-23, IL-26, IFN-beta, tumor necrosis factor [alpha], or transforming growth factor beta). These findings suggest that auto-Abs against IL-17A, IL-17F, and IL-22 may cause CMC in patients with APS-I.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

High titers of auto-Abs against IFN-α, IL-17A, IL-17F, and IL-22 in the plasma from patients with APS-I. Anti–IFN-α, –IL-17A, –IL-17F, and –IL-22 circulating IgG titers were measured by multiplex particle-based flow cytometry in 33 samples from patients with APS-I and in 37 samples from healthy controls. FI is plotted on the y axis. Representative data for two experiments are shown.

Figure 2.

Figure 2.

Specific auto-Abs against IL-17A, IL-17F, and/or IL-22 in the plasma from patients with APS-I. Western blot against rIL-17A, rIL-17F, rIL-22, and rIL-23 were performed using plasma from a healthy individual or from five patients with APS-I, diluted 1:500. Representative data for three experiments are shown. Dashed lines indicate that intervening lanes have been spliced out.

Figure 3.

Figure 3.

Neutralizing auto-Abs against IL-17A in the plasma from a patient with APS-I. IL-6 production, after 48 h of stimulation with 50 ng/ml IL-17A, by control SV-40–transformed fibroblasts incubated with 10% plasma from two controls or from one patient (APS-I patient 7; means and errors bars from duplicates are shown). The data shown are representative of two experiments.

Comment in

Similar articles

Cited by

References

    1. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., Sallusto F., Napolitani G. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639–646 10.1038/ni1467 - DOI - PubMed
    1. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., von Boehmer H., Bronson R., Dierich A., Benoist C., Mathis D. 2002. Projection of an immunological self shadow within the thymus by the aire protein. Science. 298:1395–1401 10.1126/science.1075958 - DOI - PubMed
    1. Chapgier A., Kong X.F., Boisson-Dupuis S., Jouanguy E., Averbuch D., Feinberg J., Zhang S.Y., Bustamante J., Vogt G., Lejeune J., et al. 2009. A partial form of recessive STAT1 deficiency in humans. J. Clin. Invest. 119:1502–1514 10.1172/JCI37083 - DOI - PMC - PubMed
    1. Conti H.R., Shen F., Nayyar N., Stocum E., Sun J.N., Lindemann M.J., Ho A.W., Hai J.H., Yu J.J., Jung J.W., et al. 2009. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206:299–311 10.1084/jem.20081463 - DOI - PMC - PubMed
    1. de Beaucoudrey L., Puel A., Filipe-Santos O., Cobat A., Ghandil P., Chrabieh M., Feinberg J., von Bernuth H., Samarina A., Jannière L., et al. 2008. Mutations in STAT3 and IL12RB1 impair the development of human IL-17–producing T cells. J. Exp. Med. 205:1543–1550 10.1084/jem.20080321 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources